. Altered dose response to -agonists in SERCA1a-expressing hearts ex vivo and in vivo. Am J Physiol Heart Circ Physiol 283: H958-H965, 2002; 10.1152/ ajpheart.00078.2002. -In this study we evaluated the contractile characteristics of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA)1a-expressing hearts ex vivo and in vivo and in particular their response to -adrenergic stimulation. Analysis of isolated, work-performing hearts revealed that transgenic (TG) hearts develop much higher maximal rates of contraction and relaxation than wild-type (WT) hearts. Addition of isoproterenol only moderately increased the maximal rate of relaxation (ϩ20%) but did not increase contractility or decrease relaxation time in TG hearts. Perfusion with varied buffer Ca 2ϩ concentrations indicated an altered dose response to Ca 2ϩ . In vivo TG hearts displayed fairly higher maximal rates of contraction (ϩ 25%) but unchanged relaxation parameters and a blunted but significant response to dobutamine. Our study also shows that the phospholamban (PLB) level was decreased (Ϫ40%) and its phosphorylation status modified in TG hearts. This study clearly demonstrates that increases in SERCA protein level alter the -adrenergic response and affect the phosphorylation of PLB. Interestingly, the overall cardiac function in the live animal is only slightly enhanced, suggesting that (neuro)hormonal regulations may play an important role in controlling in vivo heart function. transgenic mice; contractility; sarco(endo)plasmic reticulum calcium adenosinetriphosphatase; phospholamban SEVERAL STUDIES HAVE SHOWN that sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA) activity is decreased in animal models of cardiac hypertrophy and failure as well as in human heart failure (11). This decrease in sarcoplasmic reticulum (SR) Ca 2ϩ transport function was thought to contribute to abnormalities in Ca 2ϩ handling and contractile dysfunction in failing hearts (14). Adenoviral gene transfer of SERCA is currently being explored as a new therapeutic approach for the treatment of heart failure (7,(26)(27)(28)(29).Recent studies have shown that the fast-twitch skeletal muscle isoform SERCA1 has a higher Ca 2ϩ uptake activity than the cardiac isoform SERCA2a because of a higher Ca 2ϩ turnover rate when expressed in cardiac myocytes (34). To test whether SERCA1a can functionally substitute for SERCA2a and increase cardiac contractility, we have developed a transgenic (TG) mouse model expressing SERCA1a in the heart (16,19,23). In this model, SERCA1a expression resulted in a 2.5-fold increase in total SERCA pump protein level, but the expression of the endogenous SERCA2a isoform was reduced to ϳ50% in TG hearts. As a consequence 20% of the total number of SERCA pumps in TG hearts were type 2a whereas the majority of 80% were type 1a pumps. The contractility of isolated TG hearts was clearly increased despite the reduced expression of SERCA2a (23). SERCA1a pump expression was well tolerated without any signs of hypertrophy or other pathophysiological changes in the...